Dermatomyositis Clinical Trial
Official title:
Evaluation of Severity in Juvenile Dermatomyositis and Adult-onset Dermatomyositis: a National Multicentric Retrospective Study
Dermatomyositis (DM) are rare and heterogeneous systemic autoimmune diseases, characterized by the association of muscle inflammation, skin inflammation and vasculopathy. DM concern both adults and children. DM can be life-threatening (interstitial lung disease, infectious complications) and responsible of significant functional disability (muscle weakness). Age of onset appear to be an independent prognostic factor. Juvenile-onset DM is characterized by a higher frequency of calcinosis, skin ulceration and digestive vasculitis. In adults, interstitial lung disease and cancer are more frequent with higher mortality. Data concerning the comparison of the initial severity between juvenile and adult-onset DM are limited. The main objective is to compare global severity between juvenile DM and adult-onset DM at initial diagnosis. Secondary objectives are: - to compare organ-specific severity between juvenile DM and adult-onset DM at diagnosis. - to compare damage during follow-up and at last follow-up between juvenile DM and adult-onset DM. - to compare activity at the last follow-up between juvenile DM and adult-onset DM. - to compare iatrogenic complications between juvenile DM and adult-onset DM.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05833711 -
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
|
Phase 2 | |
| Completed |
NCT01906372 -
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
|
Phase 2 | |
| Completed |
NCT01813617 -
Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis
|
N/A | |
| Completed |
NCT01165008 -
Anakinra in Myositis
|
Phase 2/Phase 3 | |
| Completed |
NCT00004357 -
Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
|
Phase 2 | |
| Recruiting |
NCT05832034 -
Add-on Intravenous Immunoglobulins in Early Myositis
|
Phase 2 | |
| Recruiting |
NCT05979441 -
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
|
Phase 3 | |
| Not yet recruiting |
NCT05027152 -
Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties
|
N/A | |
| Active, not recruiting |
NCT04723303 -
Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)
|
Early Phase 1 | |
| Completed |
NCT03267277 -
Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05437263 -
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
|
Phase 3 | |
| Active, not recruiting |
NCT04044690 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
|
Phase 3 | |
| Recruiting |
NCT05523167 -
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03324152 -
Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis
|
N/A | |
| Completed |
NCT02043548 -
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
|
Phase 2 | |
| Completed |
NCT03414086 -
Predictor of Clinical Response to Acthar in Myositis
|
||
| Completed |
NCT04628936 -
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
|
Phase 2 | |
| Recruiting |
NCT03293615 -
Exercise Capacity of Patients With Dermatomyosis
|
N/A | |
| Completed |
NCT06002750 -
Evaluation of Tp-e Interval and Tp-e/QT Ratio in Dermatomyositis and Analysis of Their Relationship With Inflammation
|
||
| Completed |
NCT02612857 -
Trial of IMO-8400 in Adult Patients With Dermatomyositis
|
Phase 2 |